This is the authors' abstract. We don't add key points for this paper.
Prevalent urological cancers, including kidney, prostate, bladder, and testicular cancers, contribute significantly to global cancer incidence and mortality. Metabolomics, focusing on small-molecule intermediates, has emerged as a tool to understand cancer etiology. Given the knowledge gap in this field, we employ a two-sample Mendelian randomization (MR) analysis to investigate the causal relationships between genetically determined metabolites (GDMs) and the susceptibility to four common urological cancers.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: